The Mason, Ohio-based company said it expects to post sales of $49.9 million, which reflects growth of approximately 18.5% over its third quarter from the previous fiscal year.
US-based revenue is expected to be $39.8 million, while international sales are expected to be $10.2 million, the company said. Atricure said it expects to post losses of between $6 and $7.5 million for the quarter.
The preliminary sales expectations are just ahead of the $46.8 million consensus on Wall Street.
“Our third quarter performance demonstrated continued strong revenue growth and operational performance driven by our appendage management and open franchises. In addition to achieving revenue growth of 18.5% over the third quarter of 2017, we recently completed enrollment in the Converge pivotal trial, surpassed the 150,000 AtriClip milestone and benefitted from sales of our AtriClip PRO•V and Flex•V products, which launched in the past year,” prez & CEO Mike Carrel said in a prepared release.
Shares in Atricure have fallen approximately 5.2% so far today, at $31.95 as of 12:49 p.m. EDT.
In August, Atricure posted second quarter earnings that beat expectations on Wall Street and lifted its sales guidance for the remaining year.